316例变应性鼻炎患者匆忙免疫治疗的安全性及相关危险因素分析

Q4 Medicine
M Y Wei, X H Zhu, Y T Xiao, W M Luo
{"title":"316例变应性鼻炎患者匆忙免疫治疗的安全性及相关危险因素分析","authors":"M Y Wei, X H Zhu, Y T Xiao, W M Luo","doi":"10.3760/cma.j.cn115330-20241017-00585","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective:</b> To assess the safety and to identify risk factors associated with systemic adverse effects (SAEs) during the dose-escalation phase of rush immunotherapy (RIT) in patients with allergic rhinitis (AR). <b>Methods:</b> A retrospective analysis was conducted in 316 house dust mite-allergic patients diagnosed with AR who underwent RIT at the Second Affiliated Hospital of Nanchang University between February 2012 and August 2024, including 206 males and 110 females aging from 5 to 58 years old. The number of patients experiencing SAEs, the frequency of SAE incidents, and the severity grades of SAEs during the dose-escalation phase were analyzed. Associations between SAE occurrence and 19 potential factors, including demographic characteristics, serological parameters, and pulmonary function parameters, were investigated. Data were analyzed using IBM SPSS Statistics version 26.0. <b>Results:</b> Among the 316 patients, 4 358 RIT injections were administered during the dose-escalation phase. SAEs occurred in 45 patients (14.24%, 45/316), accounting for 57 distinct SAE incidents. The SAE incidence rate per injection was 1.31%. Of the 57 SAEs, 34 (59.65%) were Grade Ⅰ, 5 (8.77%) were Grade Ⅱ, and 18 (31.58%) were Grade Ⅲ. No Grade Ⅳ or Ⅴ SAEs were observed. SAE occurrence demonstrated significant associations with: age (<i>Z</i>=-2.73, <i>P</i>=0.006), body mass index (BMI; <i>t</i>=4.08, <i>P</i><0.001), skin prick test reaction intensity (<i>χ²</i>=10.34, <i>P</i>=0.006), eosinophil count (<i>Z</i>=-2.19, <i>P</i>=0.028), eosinophil percentage (<i>Z=</i>-2.59, <i>P</i>=0.010), forced expiratory volume in one second (FEV₁; <i>Z</i>=-2.04, <i>P</i>=0.042), peak expiratory flow (PEF; <i>Z</i>=-2.44, <i>P</i>=0.015). Multivariate logistic regression analysis identified BMI as an independent risk factor for SAEs (<i>OR</i>=0.86; 95%<i>CI</i>: 0.75-0.99; <i>P</i>=0.034). <b>Conclusions:</b> During the RIT dose-escalation phase for house dust mite-allergic AR patients, the incidence of SAEs was approximately 1.31% per injection. SAEs were predominantly mild (Grade Ⅰ), consistent with a favorable overall safety profile. BMI was identified as a statistically significant risk factor for SAE occurrence.</p>","PeriodicalId":23987,"journal":{"name":"Chinese journal of otorhinolaryngology head and neck surgery","volume":"60 8","pages":"954-960"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Analysis of the safety and associated risk factors of rush immunotherapy in 316 patients with allergic rhinitis].\",\"authors\":\"M Y Wei, X H Zhu, Y T Xiao, W M Luo\",\"doi\":\"10.3760/cma.j.cn115330-20241017-00585\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Objective:</b> To assess the safety and to identify risk factors associated with systemic adverse effects (SAEs) during the dose-escalation phase of rush immunotherapy (RIT) in patients with allergic rhinitis (AR). <b>Methods:</b> A retrospective analysis was conducted in 316 house dust mite-allergic patients diagnosed with AR who underwent RIT at the Second Affiliated Hospital of Nanchang University between February 2012 and August 2024, including 206 males and 110 females aging from 5 to 58 years old. The number of patients experiencing SAEs, the frequency of SAE incidents, and the severity grades of SAEs during the dose-escalation phase were analyzed. Associations between SAE occurrence and 19 potential factors, including demographic characteristics, serological parameters, and pulmonary function parameters, were investigated. Data were analyzed using IBM SPSS Statistics version 26.0. <b>Results:</b> Among the 316 patients, 4 358 RIT injections were administered during the dose-escalation phase. SAEs occurred in 45 patients (14.24%, 45/316), accounting for 57 distinct SAE incidents. The SAE incidence rate per injection was 1.31%. Of the 57 SAEs, 34 (59.65%) were Grade Ⅰ, 5 (8.77%) were Grade Ⅱ, and 18 (31.58%) were Grade Ⅲ. No Grade Ⅳ or Ⅴ SAEs were observed. SAE occurrence demonstrated significant associations with: age (<i>Z</i>=-2.73, <i>P</i>=0.006), body mass index (BMI; <i>t</i>=4.08, <i>P</i><0.001), skin prick test reaction intensity (<i>χ²</i>=10.34, <i>P</i>=0.006), eosinophil count (<i>Z</i>=-2.19, <i>P</i>=0.028), eosinophil percentage (<i>Z=</i>-2.59, <i>P</i>=0.010), forced expiratory volume in one second (FEV₁; <i>Z</i>=-2.04, <i>P</i>=0.042), peak expiratory flow (PEF; <i>Z</i>=-2.44, <i>P</i>=0.015). Multivariate logistic regression analysis identified BMI as an independent risk factor for SAEs (<i>OR</i>=0.86; 95%<i>CI</i>: 0.75-0.99; <i>P</i>=0.034). <b>Conclusions:</b> During the RIT dose-escalation phase for house dust mite-allergic AR patients, the incidence of SAEs was approximately 1.31% per injection. SAEs were predominantly mild (Grade Ⅰ), consistent with a favorable overall safety profile. BMI was identified as a statistically significant risk factor for SAE occurrence.</p>\",\"PeriodicalId\":23987,\"journal\":{\"name\":\"Chinese journal of otorhinolaryngology head and neck surgery\",\"volume\":\"60 8\",\"pages\":\"954-960\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-08-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Chinese journal of otorhinolaryngology head and neck surgery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/cma.j.cn115330-20241017-00585\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese journal of otorhinolaryngology head and neck surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn115330-20241017-00585","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

目的:评估变应性鼻炎(AR)患者快速免疫治疗(RIT)剂量递增阶段的安全性,并确定与全身不良反应(SAEs)相关的危险因素。方法:回顾性分析2012年2月至2024年8月在南昌大学第二附属医院行RIT的316例确诊为AR的屋尘螨过敏患者,其中男性206例,女性110例,年龄5 ~ 58岁。分析了在剂量递增阶段发生SAE的患者数量、SAE事件的频率以及SAE的严重程度等级。研究了SAE发生与19个潜在因素之间的关系,包括人口统计学特征、血清学参数和肺功能参数。数据分析采用IBM SPSS Statistics 26.0版本。结果:在316例患者中,有4 358例患者在剂量递增阶段接受了RIT注射。45例患者(14.24%,45/316)发生SAE,共57例不同的SAE事件。每次注射的SAE发生率为1.31%。57例sae中,Ⅰ级34例(59.65%),Ⅱ级5例(8.77%),Ⅲ级18例(31.58%)。未见Ⅳ级或Ⅴ级急性脑损伤。SAE的发生与年龄(Z=-2.73, P=0.006)、体重指数(BMI; t=4.08, Pχ²=10.34,P=0.006)、酸性粒细胞计数(Z=-2.19, P=0.028)、酸性粒细胞百分比(Z=-2.59, P=0.010)、一秒用力呼气量(FEV 1; Z=-2.04, P=0.042)、呼气峰流量(PEF; Z=-2.44, P=0.015)有显著相关性。多因素logistic回归分析发现BMI是急性呼吸道感染的独立危险因素(OR=0.86; 95%CI: 0.75-0.99; P=0.034)。结论:在屋尘螨过敏性AR患者的RIT剂量递增阶段,每次注射SAEs的发生率约为1.31%。sae主要是轻微的(Ⅰ级),与良好的总体安全性相一致。BMI被确定为SAE发生的统计学显著危险因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[Analysis of the safety and associated risk factors of rush immunotherapy in 316 patients with allergic rhinitis].

Objective: To assess the safety and to identify risk factors associated with systemic adverse effects (SAEs) during the dose-escalation phase of rush immunotherapy (RIT) in patients with allergic rhinitis (AR). Methods: A retrospective analysis was conducted in 316 house dust mite-allergic patients diagnosed with AR who underwent RIT at the Second Affiliated Hospital of Nanchang University between February 2012 and August 2024, including 206 males and 110 females aging from 5 to 58 years old. The number of patients experiencing SAEs, the frequency of SAE incidents, and the severity grades of SAEs during the dose-escalation phase were analyzed. Associations between SAE occurrence and 19 potential factors, including demographic characteristics, serological parameters, and pulmonary function parameters, were investigated. Data were analyzed using IBM SPSS Statistics version 26.0. Results: Among the 316 patients, 4 358 RIT injections were administered during the dose-escalation phase. SAEs occurred in 45 patients (14.24%, 45/316), accounting for 57 distinct SAE incidents. The SAE incidence rate per injection was 1.31%. Of the 57 SAEs, 34 (59.65%) were Grade Ⅰ, 5 (8.77%) were Grade Ⅱ, and 18 (31.58%) were Grade Ⅲ. No Grade Ⅳ or Ⅴ SAEs were observed. SAE occurrence demonstrated significant associations with: age (Z=-2.73, P=0.006), body mass index (BMI; t=4.08, P<0.001), skin prick test reaction intensity (χ²=10.34, P=0.006), eosinophil count (Z=-2.19, P=0.028), eosinophil percentage (Z=-2.59, P=0.010), forced expiratory volume in one second (FEV₁; Z=-2.04, P=0.042), peak expiratory flow (PEF; Z=-2.44, P=0.015). Multivariate logistic regression analysis identified BMI as an independent risk factor for SAEs (OR=0.86; 95%CI: 0.75-0.99; P=0.034). Conclusions: During the RIT dose-escalation phase for house dust mite-allergic AR patients, the incidence of SAEs was approximately 1.31% per injection. SAEs were predominantly mild (Grade Ⅰ), consistent with a favorable overall safety profile. BMI was identified as a statistically significant risk factor for SAE occurrence.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.40
自引率
0.00%
发文量
12432
期刊介绍: Chinese journal of otorhinolaryngology head and neck surgery is a high-level medical science and technology journal sponsored and published directly by the Chinese Medical Association, reflecting the significant research progress in the field of otorhinolaryngology head and neck surgery in China, and striving to promote the domestic and international academic exchanges for the purpose of running the journal. Over the years, the journal has been ranked first in the total citation frequency list of national scientific and technical journals published by the Documentation and Intelligence Center of the Chinese Academy of Sciences and the China Science Citation Database, and has always ranked first among the scientific and technical journals in the related fields. Chinese journal of otorhinolaryngology head and neck surgery has been included in the authoritative databases PubMed, Chinese core journals, CSCD.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信